Clinical data shows that approximately 5% of tirzepatide users and a slightly higher percentage of semaglutide users experience noticeable hair loss
Discover how microdosing unlocks a safer, more sustainable approach
Manufacturer savings programs significantly reduce costs
They were individuals with obesity or overweight, many with type 2 diabetes
The first week is typically uneventful from a weight loss perspective
doi: 10.3389/fimmu.2025.1610368 Received 11 April 2025 Accepted 26 June 2025 Published 15 July 2025 Volume 16 - 2025 Edited by Li-Tung Huang, Kaohsiung Chang Gung Memorial Hospital, Taiwan Reviewed by Beata Kasztelan-Szczerbinska, Medical University of Lublin, Poland Edit Posta, University of Debrecen, Hungary Updates Copyright 2025 Migliorisi, Gabbiadini, Dal Buono, Ferraris, Privitera, Petronio, Bertoli, Bezzio and Armuzzi